Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 18.9% in March

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 13,996 shares, a drop of 18.9% from the February 26th total of 17,248 shares. Based on an average daily volume of 3,198 shares, the short-interest ratio is presently 4.4 days. Approximately 0.0% of the shares of the stock are short sold.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Monday, December 22nd. TD Cowen reissued a “buy” rating on shares of Molecular Partners in a research note on Monday, March 16th. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Molecular Partners in a research note on Monday, March 16th. Finally, JPMorgan Chase & Co. lowered their price target on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a report on Monday, December 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Molecular Partners has an average rating of “Hold” and an average target price of $8.38.

Molecular Partners Stock Performance

Molecular Partners stock traded up $0.02 during mid-day trading on Wednesday, hitting $3.99. 3,732 shares of the company traded hands, compared to its average volume of 4,514. Molecular Partners has a one year low of $3.36 and a one year high of $5.36. The stock has a market cap of $161.18 million, a price-to-earnings ratio of -2.01 and a beta of 1.03. The stock has a fifty day moving average price of $4.56 and a 200-day moving average price of $4.23.

Molecular Partners (NASDAQ:MOLN) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). Sell-side analysts predict that Molecular Partners will post -1.93 EPS for the current year.

Institutional Investors Weigh In On Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is owned by hedge funds and other institutional investors.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.